Scott Tagawa, MD
Contrary to previous data, denosumab (Xgeva) was shown to decrease the risk of fracture without a higher incidence of cataracts in patients with nonmetastatic prostate cancer, according to results from a phase III trial presented at the 2018 ESMO Congress.
Men with nonmetastatic prostate cancer who are treated with androgen deprivation therapy (ADT) experience bone loss that may be associated with higher fracture risk and reduced survival. In a previous study, low-dose denosumab significantly increased bone mass and reduced vertebral fracture risk in these patients. However, unlike other randomized trials that evaluated denosumab, this study showed that this drug resulted in an increased development of cataracts in those who received it compared with those who were given placebo, said Scott T. Tagawa, MD, MS.
“We wanted to prove if these [earlier] results were real and not just a fluke, so we undertook this newer study,” Tagawa said.
... to read the full story